TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04437082

Intervention type: DEVICE
Intervention: optical coherence tomography
Description: imaging structural and vascular features of the eye

Intervention type: DEVICE
Intervention: optical coherence tomography
Description: imaging structural and vascular features of the eye

Intervention type: DEVICE
Intervention: optical coherence tomography
Description: imaging structural and vascular features of the eye

Intervention type: DEVICE
Intervention: optical coherence tomography
Description: imaging structural and vascular features of the eye
Study: NCT04979819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity endurance test (UULEX)
Description: Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
Study: NCT05679492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meplazumab foe injection
Description: Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study: NCT04873375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
Study: NCT06050460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA55 Injection
Description: Novel coronavirus broad-spectrum neutralizing antibody SA55 injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SA55 injection
Description: Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
Study: NCT05194410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First 3 months of virtual, team-based exercise
Description: Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Second 3 months of virtual, team-based exercise
Description: Same as above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second 3 months of virtual, team-based exercise
Description: Same as above
Study: NCT05244356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Study: NCT05027373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-613
Description: SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
Study: NCT05244356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Study: NCT05786781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transarterial CT angiography
Description: Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
Study: NCT05384197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced regimen
Description: Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended regimen
Description: Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)
Study: NCT06565559

Intervention type: DEVICE
Intervention: Wearable Wireless Sensor
Description: Stage III is a shadow mode evaluation of the device with participants wearing sensors pre-, intra-, and post-operatively. Sensor and clinical data will be collected contemporaneously in the clinical environment. No sensor data is made available to clinical teams for decision making, with no change in patient care.
Study: NCT06416007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice therapy (LRT)
Description: 5 Fractions LRT
Study: NCT05626231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender-Affirming Psychotherapy (GAP) Training
Description: The GAP training is a modular online asynchronous training intervention designed to increase mental health providers' use of gender-affirming practices with GMY (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (GMY, their caregivers, mental health providers). In this open trial, GAP training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein).
Study: NCT03806478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1105
Description: The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1105
Description: The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1105
Description: The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
Study: NCT06349434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoMo
Description: To evaluate the usefulness of extended utilization of an upper extremity assistive device, called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury (SCI).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: To evaluate the usefulness of extended conventional therapy compared to the utilization of an upper extremity assistive device called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury.
Study: NCT06117982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: Subcutaneous injection of 0.5 ml of Neupogen at a concentration of 300 micrograms/day for 4 consecutive days
Study: NCT06418360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR
Description: Transfer Energy Capacitative and Resistive Therapy
Study: NCT05244356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Study: NCT06464835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
Study: NCT06632041

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Study haemtological disturbances in neonates with necrotizing enterocolities

Intervention type: OTHER
Intervention: Complete blood count
Description: Haemtological disturbances in neonates with necrotizing enterocolities
Study: NCT06627504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health and Circadian Timing Intervention
Description: Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
Study: NCT05950802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Higher dose than traditional conditioning chemo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Higher dose than traditional conditioning chemo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Higher dose than traditional conditioning chemo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TLI
Description: radiation given with conditioning chemo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TLI
Description: radiation given with conditioning chemo
Study: NCT05020860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV administered on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen.
Study: NCT04824547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: All exercises programs will applied two sessions per week, totally eight week..

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: All exercises programs will applied two sessions per week, totally eight week..
Study: NCT06069492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat-containing food
Description: One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat-containing food
Description: One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)
Study: NCT05306223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline uncoated tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin filmcoated will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin filmcoated will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid tablets will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid tablets will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protionamide
Description: Protionamide enteric-coated tablets will be administered orally.
Study: NCT05566626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperspectral retinal image
Description: Hyperspectral image of both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mydriacyl Ophthalmic Product
Description: Mydriatic drops before retinoscopy
Study: NCT05746676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: in treatment of periodontal defects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: in treatment of periodontal defects
Study: NCT05793827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Hatha Yoga
Description: Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Impact Exercise
Description: This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity